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Volume 52, Number 4 Abstracts 1113Compared with patients who underwent ligation, patients receiving TIVS
had fewer amputations (47% vs 0%) and fewer fasciotomy procedures (93% vs
43%; P  .05). Mortality was 72% in the ligation group vs 43% in the TIVS
group. In the patients treated with a TIVS, no TIVS thrombosed, and the
mean shunt time was 22.3 hours.
Comment: Temporary intravascular shunts have long been used as a
method of temporarily restoring arterial circulation in patients with periph-
eral arterial injuries distal to the axillary crease and inguinal ligament.
Prolonged use for maintaining arterial circulation after injuries at other sites
is less recognized. The article indicates that a major vascular injury within the
abdomen does not necessarily need to be acutely repaired in damage control
situations. A shunt can be placed, the patient resuscitated, and the coagu-
lopathy corrected, or the patient brought back to the operating room for
interval repair of vascular and associated injuries. This may result in fewer
amputations and improved survival.
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Conclusion: Isolated gastrosoleal venous thrombosis (IGSVT) is asso-
ciated with a significant rate of venous thromboembolism (VTE), and this
rate of VTE can be reduced with therapeutic anticoagulation.
Summary:Only a few studies have focused on optimal management of
isolated IGSVT. The incidence and prevalence of IGSVT appears to be
significant, accounting for 15% to 25% of patients with lower extremity
thrombus on venous duplex examinations (J Vasc Surg 1999;30;787-91).
However, very few studies have quantified the natural history of IGSVT and
the effects of anticoagulation or no anticoagulation on IGSVT propagation
or resolution. The authors reviewed 34,426 lower extremity venous duplex
studies from their vascular laboratory during April 2002 to April 2007 andfound 784 patients with IGSVT in one or more limbs. Of these, 38 had
concurrent contralateral DVT, and 296 lacked follow-up data and were
excluded from analysis. Forty-four patients had a simultaneous confirmed
diagnosis of PE and were analyzed separately because they might have had a
deep venous thrombosis (DVT) that embolized. The remaining 406 patients
with IGSVT in 452 limbs were included in the primary analysis. Mean
follow-up of these patients was 7.5 11 months. The left limb was affected
in 47.3%, the right limb in 41.4%, and both limbs in 11.3%. Gastrocnemius
veins were involved in 60.1%, soleal veins alone in 36.5%, and both gastroc-
nemius and soleal veins in 3.4%. VTE events, defined as axial DVT or
pulmonary embolism, occurred in 76 patients (18.7%) after the diagnosis of
IGSVT. Of that 18.7%, 3.9% was pulmonary embolism, 16.3% was DVT,
and 1.5% was both PE andDVT. Incidence of VTEwas 30% (36 of 119) and
27% (13 of 48) in patients who received no or prophylactic anticoagulation,
respectively. Incidence of VTE was 12% (23 of 188) in patients treated with
therapeutic anticoagulation (P  .0003). Lack of therapeutic anticoagula-
tion (P  .017) and a history of VTE (P  .011) were independent
predictors of subsequent VTE development in patients with initial IGSVT.
IGSVT resolution during follow-up was 61.2% in patients treated with
therapeutic anticoagulation but only 40% and 41% in patients treated with
prophylactic or no anticoagulation, respectively (P  .003).
Comment:Accumulating data suggest IGSVTmay not be benign, and
its natural history may be favorably influenced by anticoagulation. However,
there is no randomized study of the efficacy of anticoagulation in patients
with IGSVT. In retrospective studies such as this, it may be that high-risk
patients for treatment with anticoagulation may have therapy withheld, and
those same risk factors contributed to the apparent adverse natural history of
IGSVT.With increasing numbers of IGSVT being recognized, a multicenter
randomized trial of the efficacy of anticoagulation in patients with IGSVT is
required to guide therapy for this increasingly commonly recognized con-
dition.
